Search Results for “research” – Page 27 – media

Just now! The National Medical Insurance Administration and the Ministry of Finance issued a document to solve the difficulty of collecting payments!

On November 11, the “Notice of the Office of the National Medical Insurance Administration and the General Office of the Ministry of Finance on Doing a Good Job in Prepayment of Medical Insurance Funds” (full text attached at the end of the article) was officially released. According to the notice, in principle, the prepayment is based on the average monthly expenditure of the relevant medical insurance funds in the previous one to three years, and the basic scale is determined, and adjusted in combination with the annual comprehensive evaluation and credit evaluation of designated medical institutions. The prepayment scale is about 1 month. The document clearly stipulates that medical insurance prepayments shall not be used for non-medical expenses such as medical institution infrastructure investment, daily operation, and debt repayment. The special prepayment of medical insurance funds for centralized volume procurement of drugs and medical consumables shall be implemented in accordance ...
- Source: drugdu
- 50
- November 13, 2024
1.82 billion, “China Resources” adds another member

On November 8, China Resources Boya Bio’s official website announced that “China Resources Boya Bio and Green Cross (China) meeting and work docking meeting were successfully held”. Two days ago (November 6), China Resources Boya Bio completed the acquisition of 100% equity of Green Cross (Hong Kong) and began to include it in the scope of consolidated financial statements. So far, “China Resources” has officially made another move in the blood products sector. In July this year, China Resources Boya Bio agreed to transfer 100% equity of Green Cross (Hong Kong) with its own funds of 1.82 billion yuan, thereby indirectly acquiring the domestic blood products entity Green Cross (China) (for details, please refer to the previous article “Spending 1.82 billion! China Resources Group takes action again”). As the blood products platform of China Resources’ big health sector, China Resources Boya Bio’s contribution to China Resources Pharmaceutical’s performance cannot be ...
- Source: drugdu
- 48
- November 13, 2024
Domestic lupus erythematosus drugs sold for 6 billion!

According to media statistics, in the first half of 2024 alone, at least 32 innovative pharmaceutical companies in China successfully completed BD projects, achieving cross-border expansion and involving transaction amounts exceeding 20 billion US dollars, with a significant increase in quantity compared to previous years. And this trend continues into the second half of the year, with domestic innovative pharmaceutical companies such as Ruige Pharmaceutical, Jiahe Biotechnology, Tongrun Biotechnology, and Anmai Biotechnology all having significant BD transactions. Recently, a domestic innovative pharmaceutical company that has only been established for eight years and currently has only a few pipelines under research sold one of its products, BD, for a sky high price. GlaxoSmithKline (GSK) has officially announced that it has reached an acquisition agreement with Chinese innovative pharmaceutical company Chimagin Biosciences for the three specific antibody CMG1A46. Accordingly, GSK will make a prepayment of $300 million to Enmu Biotechnology to acquire ...
- Source: drugdu
- 48
- November 12, 2024
The “trend” and “newness” behind Roche Pharmaceuticals’ layout of smart healthcare in China

Never underestimate the power of the tide. “AI+ empowerment” is becoming an important engine to promote the expansion of new quality productivity in various industries, and the medical and health system is no exception. For the medical and health system, improving productivity and efficiency while reducing the cost of patients and healthcare systems is an eternal topic. This also means that the greatest potential of AI+ healthcare lies not only in the application of one or two scenarios, but in assisting and optimizing medical services in all aspects, and completely rewriting the order of all links of “diagnosis and treatment”. At this year’s CIIE, through the display of Roche, the industry leader, we can see that this trend is already very obvious: AI is penetrating in multiple dimensions to meet the individualized diagnosis and treatment needs of patients and change the direction of the tide in multiple fields. Although many ...
- Source: drugdu
- 49
- November 12, 2024
The king of cancer is to be defeated

Pancreatic cancer is known as the “king of cancer” because of its high malignancy and lack of effective drug treatment. However, the research and development community has never stopped its efforts to conquer this type of cancer. Recently, Hengrui Medicine announced that the results of the Phase III study of irinotecan liposome (II) combined with advanced pancreatic cancer were published in the Nature sub-journal “Signal Transduction and Targeted Therapy”. The results showed that the irinotecan liposome combination regimen reduced the risk of death in pancreatic cancer patients by 37% compared with the control group. In the next era beyond chemotherapy, perhaps ADC drugs will become the main force in the fight against pancreatic cancer. For example, Innovent Biologics’ ADC targeting cluadin18.2 and Lepu Bio’s ADC targeting EGFR each have their own surprises, and both have shown breakthrough efficacy in the remission rate of pancreatic cancer. In addition, Kangfang has also ...
- Source: drugdu
- 46
- November 12, 2024
Domestic bispecific antibodies win another victory

Recently, Wellizbo announced that its independently developed and globally intellectual property-owned Class 1 new drug LBL-034 has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma (MM). LBL-034 is a new generation of humanized bispecific T cell engaging antibodies targeting GPRC5D and CD3 developed using Wellizbo’s independently developed and intellectual property-owned CD3 bispecific antibody technology platform “LeadsBodyTM”. It is the third CD3 T cell connector targeting GPRC5D to enter the clinical stage in the world. Multiple myeloma (MM) is a malignant plasma cell disease caused by abnormal proliferation of clonal plasma cells, accounting for about 10% of hematological malignancies and about 1% of all tumor diseases. MM is still an incurable malignancy. With multiple lines of medication, the interval between relapses will become shorter and shorter, and eventually evolve into RRMM, which seriously threatens the life and health of patients. ...
- Source: drugdu
- 50
- November 11, 2024
Five questions and answers about the application of drug traceability codes in medical insurance

Recently, the National Medical Insurance Administration has attracted attention through the verification of drug traceability codes. What is a drug traceability code? What does it mean if a drug traceability code is scanned repeatedly? What role does the drug traceability code play in ensuring the security of medical insurance funds? How to use drug traceability codes? What is a drug traceability code? Answer: The drug traceability code is the “electronic ID card” of the drug. It is usually composed of a series of numbers, letters and (or) symbols. It is marked in a prominent position on the drug packaging box. It is the unique identity label given to each box of drugs from the time of production. If the drug traceability code appears repeatedly during the circulation process, the drug may be a “returned drug”, a counterfeit drug, or sold in a scrambled manner. The drug traceability code has three ...
- Source: drugdu
- 47
- November 11, 2024
A biotech company was deregistered and liquidated

Recently, Asia Pacific Pharmaceuticals issued the “Announcement on the Progress of Liquidation and Cancellation of Joint Ventures”. A Biotech company that it established with an investment of approximately RMB 35.84 million in 2019 has completed the deregistration procedures. Asia Pacific Pharmaceuticals is mainly engaged in pharmaceutical manufacturing and CRO service businesses, covering chemical pharmaceutical preparations, chemical APIs, and pharmaceutical research and development. Its main products include roxithromycin capsules, cephalexin capsules, azithromycin dispersible tablets, and azithromycin for injection. The Biotech business area that was deregistered and liquidated this time was the new track that Asia Pacific Pharmaceuticals first contacted at the time – industrial hemp. It is reported that according to the different mass concentrations of tetrahydrocannabinol (THC) contained in hemp, hemp can be divided into industrial hemp, intermediate hemp, and recreational hemp. Industrial hemp refers to hemp with a THC content of less than 0.3%, which does not show psychoactive ...
- Source: drugdu
- 47
- November 11, 2024
Domestic dual antibody makes another breakthrough

Introduction: Has the best potential in its class Recently, Weili Zhibo announced that its independently developed Class 1 new drug LBL-034, which has global intellectual property rights, has been granted orphan drug status by the US Food and Drug Administration (FDA) for the treatment of multiple myeloma (MM). LBL-034 is a new generation of humanized bispecific T cell linker antibody targeting GPRC5D and CD3, developed using LeadsBody TM, a CD3 bispecific technology platform independently developed by Weili Libo with intellectual property rights. It is the third CD3 T cell linker targeting GPRC5D to enter the clinical stage worldwide. Figure 1: GPRC5D/CD3 dual antibody under global research Image source: Pharmaceutical Intelligence Data Multiple myeloma (MM) is a malignant plasma cell disease caused by abnormal proliferation of clonal plasma cells, accounting for approximately 10% of hematological malignancies and 1% of all tumor diseases. MM is still an incurable malignant tumor. With ...
- Source: drugdu
- 58
- November 9, 2024
Continuing to Increase Investment in China and Bringing Chinese Innovative Medicines to the World

“This is our third time participating in the China International Import Expo. Over the past few years, we have leveraged the platform of the expo to share our R&D achievements and business progress, while accelerating the launch of our innovative products in China to benefit more groups as soon as possible. Ultimately, through the expo, we have carried out various collaborations and signed agreements with different partners, thereby speeding up our development process in China,” said Jin Fangqian, Gilead Sciences’ Global Vice President and General Manager for China, during an interview with media outlets like Times Finance during the 7th China International Import Expo. At this year’s expo, Gilead Sciences announced significant progress regarding its core product, Lenacapavir, in the field of HIV prevention. Lenacapavir is the world’s first approved HIV capsid inhibitor and offers a long-acting treatment regimen needing administration only twice a year. The drug has been approved ...
- Source: drugdu
- 52
- November 9, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.